Literature DB >> 16187022

Therapeutic implications of interferon regulatory factor (IRF)-1 and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to interferon (IFN)-beta in glioblastoma cells and prognostic value for DIA.

Atsuo Yoshino1, Yoichi Katayama, Takakazu Yokoyama, Takao Watanabe, Akiyoshi Ogino, Takashi Ota, Chiaki Komine, Takao Fukushima, Kaoru Kusama.   

Abstract

The precise mechanisms governing the direct effect of IFN-beta, including apoptosis induction, are not yet fully understood. To gain a better insight into these mechanisms, we investigated the signaling pathways focusing particularly on interferon regulatory factor 1 (IRF-1) and IRF-2 in glioblastoma cell lines. Furthermore, we attempted to determine whether or not IRF-1 and IRF-2 act as additional prognostic indicators in diffusely infiltrating astrocytomas (DIA). We first assessed the cytotoxic effects of IFN-beta based on a cell growth study and modified MTT assay, and then quantified the apoptosis using a sandwich enzyme immunoassay following IFN-beta treatment in the cell lines, U-87MG, T98G, and A-172. Subsequently, we carried out an analysis of apoptosis-related molecules as evaluated by densitometric analysis of Western blots, focusing on IRF-1 and IRF-2, and two major initiator caspases, caspase-8 and caspase-9. Furthermore, we assessed the expression of type I IFN receptor, IRF-1, and IRF-2 using immunohistochemical techniques in 63 DIA (15 of WHO grade II, 18 of grade III, and 30 of grade IV), and analyzed their impact on prognosis. An increase in apoptosis was apparent after 48 h of IFN-beta treatment (1 x 10(4) IU/ml) in T98G but not in U-87MG or A-172. IFN-beta treatment for 6 h significantly enhanced the expression of IRF-1 in all three cell lines. However, an enhanced expression of IRF-2 was observed only in the not-most-sensitive, non-apoptosis-induced U-87MG and A-172. While minimal processing of caspase-8 was noted in the three cell lines throughout the experiment, caspase-9 activation was observed in the apoptosis-detected T98G after 48 h of treatment, as indicated by a 1.33-fold increase (P=0.037). On the other hand, the IRF-1 LI and IRF-1/IRF-2 LI ratio were greater in low-grade DAI, and were negatively correlated with the histopathological grade in DIA (P=0.017 and P=0.001, respectively). Furthermore, the IRF-1/IRF-2 LI ratio was negatively correlated with the MIB-1 LI in DIA (P=0.004), and represented an independent and most powerful determinant of overall survival compared to other conventional prognostic factors (P=0.018). However, the relation was not statistically significant when only patients with high-grade DIA were assessed. Our findings suggest that up-regulation of IRF-1 and IRF-2 might be an important determinant of susceptibility to IFN-beta mediated cytotoxicity including apoptosis. Furthermore, the IRF-1/IRF-2 LI ratio may reflect the proliferative state of DIA and constitute an important prognostic marker in DIA. Thus, IRF-1 and IRF-2 could represent one of the therapeutic target sites for the regulation of cell growth in DIA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16187022     DOI: 10.1007/s11060-004-7316-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  56 in total

Review 1.  The interferon system. A bird's eye view of its biochemistry.

Authors:  G C Sen; P Lengyel
Journal:  J Biol Chem       Date:  1992-03-15       Impact factor: 5.157

2.  Apaf1 is required for mitochondrial pathways of apoptosis and brain development.

Authors:  H Yoshida; Y Y Kong; R Yoshida; A J Elia; A Hakem; R Hakem; J M Penninger; T W Mak
Journal:  Cell       Date:  1998-09-18       Impact factor: 41.582

3.  Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma.

Authors:  K Seki; H Yoshikawa; K Shiiki; Y Hamada; N Akamatsu; K Tasaka
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

4.  Cell cycle regulation of histone H4 gene transcription requires the oncogenic factor IRF-2.

Authors:  P S Vaughan; C M van der Meijden; F Aziz; H Harada; T Taniguchi; A J van Wijnen; J L Stein; G S Stein
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

Review 5.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

6.  Oncogene-dependent regulation of caspase activation by p53 protein in a cell-free system.

Authors:  H F Ding; G McGill; S Rowan; C Schmaltz; A Shimamura; D E Fisher
Journal:  J Biol Chem       Date:  1998-10-23       Impact factor: 5.157

7.  Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2.

Authors:  H Harada; M Kitagawa; N Tanaka; H Yamamoto; K Harada; M Ishihara; T Taniguchi
Journal:  Science       Date:  1993-02-12       Impact factor: 47.728

8.  Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation.

Authors:  H Harada; T Kondo; S Ogawa; T Tamura; M Kitagawa; N Tanaka; M S Lamphier; H Hirai; T Taniguchi
Journal:  Oncogene       Date:  1994-11       Impact factor: 9.867

9.  Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation.

Authors:  J Yoshida; Y Kajita; T Wakabayashi; K Sugita
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

10.  Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.

Authors:  Thomas Mueller; Wieland Voigt; Heike Simon; Angelika Fruehauf; Andrej Bulankin; Axel Grothey; Hans-Joachim Schmoll
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

View more
  5 in total

1.  Microengineered perfusable 3D-bioprinted glioblastoma model for in vivo mimicry of tumor microenvironment.

Authors:  Lena Neufeld; Eilam Yeini; Noa Reisman; Yael Shtilerman; Dikla Ben-Shushan; Sabina Pozzi; Asaf Madi; Galia Tiram; Anat Eldar-Boock; Shiran Ferber; Rachel Grossman; Zvi Ram; Ronit Satchi-Fainaro
Journal:  Sci Adv       Date:  2021-08-18       Impact factor: 14.136

2.  Antitumorigenic effect of interferon-β by inhibition of undifferentiated glioblastoma cells.

Authors:  Shun Yamamuro; Emiko Sano; Yutaka Okamoto; Yushi Ochiai; Takashi Ohta; Akiyoshi Ogino; Atsushi Natsume; Toshihiko Wakabayashi; Takuya Ueda; Hiroyuki Hara; Tomohiro Nakayama; Atsuo Yoshino; Yoichi Katayama
Journal:  Int J Oncol       Date:  2015-09-14       Impact factor: 5.650

Review 3.  Interferon regulatory factor 1 inactivation in human cancer.

Authors:  Khaldoon Alsamman; Omar S El-Masry
Journal:  Biosci Rep       Date:  2018-05-08       Impact factor: 3.840

4.  Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.

Authors:  Franz J Zemp; Brienne A McKenzie; Xueqing Lun; Lori Maxwell; Karlyne M Reilly; Grant McFadden; V Wee Yong; Peter A Forsyth
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

5.  Antitumor effects of ribavirin in combination with TMZ and IFN-β in malignant glioma cells.

Authors:  Yushi Ochiai; Koichiro Sumi; Emiko Sano; Sodai Yoshimura; Shun Yamamuro; Akiyoshi Ogino; Takuya Ueda; Yutaka Suzuki; Tomohiro Nakayama; Hiroyuki Hara; Yoichi Katayama; Atsuo Yoshino
Journal:  Oncol Lett       Date:  2020-08-31       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.